| Literature DB >> 20448109 |
Erica Ballabio1, Tracey Mitchell, Marloes S van Kester, Stephen Taylor, Heather M Dunlop, Jianxiang Chi, Isabella Tosi, Maarten H Vermeer, Daniela Tramonti, Nigel J Saunders, Jacqueline Boultwood, James S Wainscoat, Francesco Pezzella, Sean J Whittaker, Cornelius P Tensen, Christian S R Hatton, Charles H Lawrie.
Abstract
MicroRNAs are commonly aberrantly expressed in many cancers. Very little is known of their role in T-cell lymphoma, however. We therefore elucidated the complete miRNome of purified T cells from 21 patients diagnosed with Sézary Syndrome (SzS), a rare aggressive primary cutaneous T-cell (CD4(+)) lymphoma. Unsupervised cluster analysis of microarray data revealed that the microRNA expression profile was distinct from CD4(+) T-cell controls and B-cell lymphomas. The majority (104 of 114) of SzS-associated microRNAs (P < .05) were down-regulated and their expression pattern was largely consistent with previously reported genomic copy number abnormalities and were found to be highly enriched (P < .001) for aberrantly expressed target genes. Levels of miR-223 distinguished SzS samples (n = 32) from healthy controls (n = 19) and patients with mycosis fungoides (n = 11) in more than 90% of samples. Furthermore, we demonstrate that the down-regulation of intronically encoded miR-342 plays a role in the pathogenesis of SzS by inhibiting apoptosis, and describe a novel mechanism of regulation for this microRNA via binding of miR-199a* to its host gene. We also provide the first in vivo evidence for down-regulation of the miR-17-92 cluster in malignancy and demonstrate that ectopic miR-17-5p expression increases apoptosis and decreases cell proliferation in SzS cells.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20448109 PMCID: PMC2938132 DOI: 10.1182/blood-2009-12-256719
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113